SYMPOSIA

More documents

Recommendations

Info

Poster Presentations [PP-037] Ref. No: 230 A comparison before and after using lamotrigine in long term continued treatment: the effect of blood levels Sermin Kesebir 1 , Fisun Akdeniz 2 , Aysun Demir 1 , Mustafa Bilici 1 1 Erenkoy TEHMND, Istanbul, Turkey 2 Ege University, Psychiatry, Izmir, Turkey E-mail: serminkesebir@hotmail.com Objective: The purpose of this study is that determine whether or not the efficacy of lamotrigine, which is an anticonvulsant with a stabilizer quality in neuronal membranes and has inhibitor activity in sodium and calcium channels and presynaptic neurons, is related to blood levels in bipolar disorder. We compared the period before and after lamotrigine use in bipolar cases and studied if there was any relationship between lamotrigine blood levels and clinical progress. Method: Forty cases, diagnosed with bipolar disorder type I according to the DSM-IV, and taking lamotrigine for at least two years together with any mood stabilizer (lithium, anticonvulsants or atypical antipsychotics), were evaluated consecutively. For evaluation, being in remission period was set as a criterion for these cases. Patient interviews were carried out with the SCID-I in bipolar cases. Before or after protective treatment, the SCIP-TURK Mood Disorders Diagnosis and Patient Registration Form were filled in by the patients and their relatives. Later blood samples were taken from the bipolar cases in order to analyze lamotrigine blood levels. Results: In the bipolar cases, when comparing before and after long term maintenance of lamotrigine, it was determined that after using lamotrigine, total episode and depressive episode frequency decreased, episode severity was less (p< 0.001, 0.039, and 0.04, respectively) and the fast onset and termination ratio decreased (p= 0.027). When evaluated according to these variables, in long term maintenance, the ratio of good treatment response to lamotrigine among bipolar cases was 77.5%. In cases with good treatment response to lamotrigine, while lamotrigine doses were found to be similar to the others (135.5±52.7/155.6±69.7 mg/day), lamotrigine blood levels were found to be higher (3.8±1.9/2.0±1.1 µg /ml) (p= 0.005). No correlation was shown between lamotrigine dose and lamotrigine blood levels (r= 0.185, p= 0.254). Conclusion: As a result, lamotrigine is an efficient choice in long term maintenance treatment of bipolar disorder. The relationship of this efficacy to lamotrigine blood levels must be explored in future studies. Key words: Lamotrigine, bipolar disorder, blood level Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S142 [PP-038] Ref. No: 172 ICAM, VCAM and E-selectin levels in first episode schizophrenic patients Semine Özdoğan Kavzoğlu, Aytül Gürsu Hariri Erenköy Research and Training Hospital for Neuropsychiatry, Istanbul, Turkey E-mail: sokavzoglu@hotmail.com Objective: It is known that mortality rates in schizophrenic patients with cardiovascular diseases are twice as high as other diseases. Some of the research has revealed that the risks of cardiovascular disease were dependent on adhesion molecules. The main adhesion molecules are intracellular adhesive molecule (ICAM-1), vascular cell adhesive molecule (VCAM-1) and E-selectin. The aim of this study was to determine whether or not ICAM-1, V-CAM-1 and E-selectin levels, which are considered as possible biological determinants in the prognosis and progression of atherosclerosis, change with treatment in schizophrenic patients with respect to controls. Method: In the Erenköy Research and Training Hospital for Neuropsychiatry, 50 patients who were diagnosed with first episode schizophrenia according to the DSM-IV-TR diagnostic criteria and had never received antipsychotic treatment and a control group consisting of 50 healthy volunteers were enrolled the study. At the beginning of the study (n=50) and after the third month (n=39), ICAM, VCAM, E-selectin, Fasting Blood Glucose, Total Cholesterol, LDL Cholesterol, HDL Cholesterol and Triglyceride levels were checked in the plasma of each patient and compared with each other. For the control group, the same biochemical parameters were investigated only at the beginning of the study. In order to assess the termination of the acute episode, the patient group was given the Positive Symptoms Assessment Scale (SAPS) and Negative Symptoms Assessment Scale (SANS) in the beginning and at the end of the third month. Results: In the first episode schizophrenic patients, the average age was 30.14±7.50 years. In the patients, the beginning ICAM-1 levels were lower than the control group (t= 3.41, p=0.001) and increased during treatment (t=-6.73 p
Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org Poster Presentations levels were similar to the control group (t=-1.23, p=0.223; t=-0.32 p=0.750, respectively). In addition, after treatment the VCAM-1 level was determined to be lower than the pretreatment level (t=7.17, p
Page 1 and 2:
With Contributions of
Page 3 and 4:
Turkish Association for Psychopharm
Page 5 and 6:
Nihat ALPAY Rüstem AŞKIN Ömer AY
Page 7 and 8:
NOVEMBER 23, 2011 WEDNESDAY TIME HA
Page 9 and 10:
NOVEMBER 25, 2011 FRIDAY AT A GLANC
Page 11 and 12:
13.30 15.00-16.00 17.30-19.30 17.30
Page 13 and 14:
09.00-10.30 PS-04: Adult attention
Page 15 and 16:
20.30-22.30 KC-01: Biostatistics -
Page 17 and 18:
09.00-10.30 PS-09: From preclinical
Page 19 and 20:
09.00-10.30 PS-10: Will glutamaterg
Page 21 and 22:
09.00-10.30 JS-05: Indian Psychiatr
Page 23 and 24:
NOVEMBER 26, 2011 SATURDAY 09.00-10
Page 25 and 26:
NOVEMBER 27, 2011 SUNDAY 09.00-10.3
Page 27 and 28:
Author(s) Abstracts of the Invited
Page 29 and 30:
Author(s) Abstracts of the Invited
Page 31 and 32:
Author(s) Poster Presentation 16 A.
Page 33 and 34:
Author(s) Poster Presentation 60 Ba
Page 35:
Author(s) Poster Presentation 108 O
Page 38 and 39:
Abstracts of the Invited Speakers O
Page 40 and 41:
Abstracts of the Invited Speakers p
Page 42 and 43:
Abstracts of the Invited Speakers D
Page 44 and 45:
Abstracts of the Invited Speakers R
Page 46 and 47:
Abstracts of the Invited Speakers [
Page 48 and 49:
Abstracts of the Invited Speakers H
Page 50 and 51:
Abstracts of the Invited Speakers m
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Abstracts of the Invited Speakers d
Page 58 and 59:
Abstracts of the Invited Speakers e
Page 60 and 61:
Abstracts of the Invited Speakers d
Page 62 and 63:
Abstracts of the Invited Speakers S
Page 64 and 65:
Abstracts of the Invited Speakers o
Page 66 and 67:
Abstracts of the Invited Speakers N
Page 68 and 69:
Abstracts of the Invited Speakers I
Page 70 and 71:
Abstracts of the Invited Speakers E
Page 72 and 73:
Abstracts of the Invited Speakers G
Page 74 and 75:
Abstracts of the Invited Speakers T
Page 76 and 77:
Abstracts of the Invited Speakers A
Page 78 and 79:
Abstracts of the Invited Speakers l
Page 80 and 81:
Abstracts of the Invited Speakers E
Page 82 and 83:
Page 84 and 85:
Abstracts of the Invited Speakers i
Page 86 and 87:
Abstracts of the Invited Speakers
Page 88 and 89:
Page 90 and 91:
Abstracts of the Invited Speakers A
Page 92 and 93:
Abstracts of the Invited Speakers P
Page 94 and 95:
Page 96 and 97: Abstracts of the Invited Speakers R
Page 98 and 99: Abstracts of the Invited Speakers O
Page 100 and 101: Abstracts of the Invited Speakers T
Page 102 and 103: Abstracts of the Invited Speakers e
Page 104 and 105: Abstracts of the Invited Speakers o
Page 106 and 107: Abstracts of the Invited Speakers S
Page 108 and 109: Abstracts of the Invited Speakers C
Page 110 and 111: Abstracts of the Invited Speakers [
Page 112 and 113: Abstracts of Oral Presentations [SO
Page 114 and 115: Abstracts of Oral Presentations Mat
Page 116 and 117: Abstracts of Oral Presentations wit
Page 118 and 119: Abstracts of Oral Presentations pat
Page 120 and 121: Abstracts of Oral Presentations ade
Page 122 and 123: Abstracts of Oral Presentations eff
Page 124 and 125: Turkish Association for Psychopharm
Page 126 and 127: Poster Presentations behavior by ex
Page 128 and 129: Poster Presentations [PP-005] Ref.
Page 130 and 131: Poster Presentations fulfilling the
Page 134 and 135: Poster Presentations eating disorde
Page 136 and 137: Poster Presentations Conclusion: Th
Page 138 and 139: Poster Presentations had no treatme
Page 140 and 141: Poster Presentations 80 mg/day (dos
Page 154 and 155: Poster Presentations Based on the r
Page 160 and 161: Poster Presentations study, the Cro
Page 168 and 169: Poster Presentations motivations fo
Page 172 and 173: Poster Presentations 4. Şükrü Ka
Page 176 and 177: Poster Presentations References: 1.
Page 178 and 179: Poster Presentations when meeting a
Page 180 and 181: Poster Presentations MADRS and HAM-
Page 182 and 183: Poster Presentations in terms of co
Page 184 and 185: Poster Presentations schizophrenia
Page 186 and 187: Poster Presentations ascending dopa
Page 188 and 189: Poster Presentations study. The inc
Page 190 and 191: Poster Presentations and Spaniards.
Page 192 and 193: Poster Presentations patients, and
Page 196 and 197:
Poster Presentations [PP-113] Ref.
Page 198 and 199:
Poster Presentations [PP-116] Ref.
Page 200 and 201:
Poster Presentations 22.7%, bipolar
Page 202 and 203:
Poster Presentations future, we exp
Page 204 and 205:
Poster Presentations of action, ami
Page 206 and 207:
Poster Presentations pharmacologica
Page 208 and 209:
(±)-3-4-methylenedioxymethamphetam
Page 210 and 211:
Panic symptoms S122 Paroxetine S156
Page 212 and 213:
Etli T. S162 Evren C. S80, S154, S1
show all

SYMPOSIA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?